Spaces:
Running
Running
File size: 90,070 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 4,
"metadata": {},
"outputs": [],
"source": [
"import pandas as pd\n",
"import torch\n",
"from transformers import AutoTokenizer, AutoModel\n",
"import re"
]
},
{
"cell_type": "code",
"execution_count": 2,
"metadata": {},
"outputs": [],
"source": [
"# Target列を分割する関数\n",
"def split_target(target):\n",
" # 指定された区切り文字で分割\n",
" split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
" # 空白文字を除外してリストとして返す\n",
" return [word.strip() for word in split_words if word.strip()]"
]
},
{
"cell_type": "code",
"execution_count": 3,
"metadata": {},
"outputs": [],
"source": [
"basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n",
"basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
"# Target列を分割してTargetWord列を追加\n",
"basedf['TargetWord'] = basedf['Target'].apply(split_target)"
]
},
{
"cell_type": "code",
"execution_count": 5,
"metadata": {},
"outputs": [
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "9671f824f52348f8a161a130e7437adb",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"tokenizer_config.json: 0%| | 0.00/418 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "6da34a9d4894446292efdc8b26959431",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"sentencepiece.bpe.model: 0%| | 0.00/5.07M [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "497e9ea0ccdb4efcb40f33fc7f48f7e9",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"tokenizer.json: 0%| | 0.00/17.1M [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "9f5ddefc537d40cfa4c1cc74431c0558",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"special_tokens_map.json: 0%| | 0.00/280 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "fe3dcf900fe5496eb5fb5773535e122c",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"config.json: 0%| | 0.00/690 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "046a5fa146b943c7914a9d9be475fe9b",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"model.safetensors: 0%| | 0.00/2.24G [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
}
],
"source": [
"# モデルとトークナイザーのロード\n",
"model_name = \"intfloat/multilingual-e5-large\"\n",
"tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
"model = AutoModel.from_pretrained(model_name)"
]
},
{
"cell_type": "code",
"execution_count": 6,
"metadata": {},
"outputs": [],
"source": [
"# テキストをベクトル化する関数\n",
"def encode_text(texts):\n",
" inputs = tokenizer(texts, padding=True, truncation=True, return_tensors=\"pt\")\n",
" with torch.no_grad():\n",
" outputs = model(**inputs)\n",
" return outputs.last_hidden_state.mean(dim=1) # 平均プーリングでベクトル化"
]
},
{
"cell_type": "code",
"execution_count": 66,
"metadata": {},
"outputs": [],
"source": [
"# クエリ\n",
"query = \"乳がん\"\n",
"#query = \"神経膠腫\"\n",
"threshold = 0.91\n",
"#threshold = 0.875\n",
"# クエリをベクトル化\n",
"query_vec = encode_text([query])"
]
},
{
"cell_type": "code",
"execution_count": 67,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"torch.Size([1, 1024])"
]
},
"execution_count": 67,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"query_vec.shape"
]
},
{
"cell_type": "code",
"execution_count": 68,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCT2041240130</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
" <td>肺がん</td>\n",
" <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
" <td>(1) Patients with a history of allergy to the ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Treatment group\\r\\nAdminister GRA 1mg intraven...</td>\n",
" <td>[肺がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>59</th>\n",
" <td>jRCT2031240404</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>転移性HR+/HER2-乳がん及びその他の進行性固形がん患者を対象にCDK4阻害剤BGB-4...</td>\n",
" <td>・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳...</td>\n",
" <td>サイクリン依存性キナーゼ 4 (CDK4) 阻害剤である BGB-43395 が、ホルモン受...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Phase 1a (Dose Escalation) and 1b (Dose Expan...</td>\n",
" <td>-Prior therapy selectively targeting CDK4 (pri...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: BGB-43395\\r\\nPlanned doses administered...</td>\n",
" <td>[進行性固形腫瘍, 進行性乳がん, 転移性乳がん, ホルモン受容体陽性乳がん, ホルモン受容...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>201</th>\n",
" <td>jRCT2052240059</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
" <td>乳がん</td>\n",
" <td>HSD17B4高メチル化（HSD17B4 hypermethylation：HH）を有するH...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Histologically confirmed invasive breast ca...</td>\n",
" <td>1. History of other malignancy within the last...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Omitting breast surgery after preoperative che...</td>\n",
" <td>[乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>234</th>\n",
" <td>jRCT2031240065</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>DNAミスマッチ修復機構欠損を有する進行性・転移性子宮体がん患者を対象に、一次治療として化学...</td>\n",
" <td>子宮体がん</td>\n",
" <td>dMMR/MSI-Hを有する再発又は進行子宮体癌患者を対象にdostarlimabの有効性及...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Female patient is at least 18 years of age,...</td>\n",
" <td>1. Patient has received neoadjuvant/adjuvant s...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will be randomized 1:1 to receive eit...</td>\n",
" <td>[子宮体がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>257</th>\n",
" <td>jRCT2033240023</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>免疫チェックポイント阻害剤に対してacquired resistanceとなったがん患者を対...</td>\n",
" <td>肺がん、食道がん、胃癌等の固形がん</td>\n",
" <td>免疫チェックポイント阻害剤に対してacquired resistanceとなったがん患者（非...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Japanese patients aged 20 years or older at...</td>\n",
" <td>1. Patients with a history of severe drug hype...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Intramuscular injection of the investigational...</td>\n",
" <td>[肺がん, 食道がん, 胃癌等の固形がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>271</th>\n",
" <td>jRCT2031230750</td>\n",
" <td>NCT06188559</td>\n",
" <td>NaN</td>\n",
" <td>治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，...</td>\n",
" <td>HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌</td>\n",
" <td>治療</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Male or female, aged >=18 years at the tim...</td>\n",
" <td>(1) Presence of brain or subdural metastases, ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Generic Name:NA\\r\\nStudy Treatment in dose opt...</td>\n",
" <td>[HER2 陽性, HER2 低発現の切除不能, 転移性乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>279</th>\n",
" <td>jRCT2031230723</td>\n",
" <td>NCT06112379</td>\n",
" <td>NaN</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>乳癌</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Participant must be >= 18 years at the time...</td>\n",
" <td>1. As judged by the investigator, any evidence...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>311</th>\n",
" <td>jRCT2061230102</td>\n",
" <td>NCT06103864</td>\n",
" <td>NaN</td>\n",
" <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
" <td>乳癌</td>\n",
" <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Histologically or cytologically documented loc...</td>\n",
" <td>As judged by investigator, severe or uncontrol...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd + durvalumab\\r\\nArm 2: Investi...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>396</th>\n",
" <td>jRCT2061230074</td>\n",
" <td>NCT05952557</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men; 18 years or more at the time ...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[乳がん, 早期乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>467</th>\n",
" <td>jRCT2031230249</td>\n",
" <td>NCT05753501</td>\n",
" <td>NaN</td>\n",
" <td>[M23-647]B細胞性悪性腫瘍患者を対象としたBTK 分解誘導化合物ABBV-101 の...</td>\n",
" <td>血液がん</td>\n",
" <td>・ABBV-101 の安全性を明らかにし，忍容性を確認する\\r\\n・ABBV-101 の経口...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-For Dose Escalation (Part 1) only: Participan...</td>\n",
" <td>-Previously treated with a Bruton's tyrosine k...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: ABBV-101\\r\\nOral: Tablet</td>\n",
" <td>[血液がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>509</th>\n",
" <td>jRCT2031230109</td>\n",
" <td>NCT05514054</td>\n",
" <td>NaN</td>\n",
" <td>EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...</td>\n",
" <td>乳癌</td>\n",
" <td>早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Have a diagnosis of ER+, HER2- early-stage, r...</td>\n",
" <td>-Have any evidence of metastatic disease (incl...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: Imlunestrant\\r\\n Administered orally.\\...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>514</th>\n",
" <td>jRCT2031230090</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...</td>\n",
" <td>再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん</td>\n",
" <td>再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Dose Escalation and Dose Expansion Cohorts\\r\\n...</td>\n",
" <td>Dose Escalation and Expansion Cohorts\\r\\n1.\\tW...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>This is a Phase I dose escalation/expansion mu...</td>\n",
" <td>[再発, 難治性の局所進行性, 転移性乳がん, トリプルネガティブ乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>515</th>\n",
" <td>jRCT2031230096</td>\n",
" <td>NCT05774951</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men, greater than or equal to 18 y...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[乳がん, 早期乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>582</th>\n",
" <td>jRCT2051220176</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>切除不能進行再発食道がん及び胃がんに対する免疫チェックポイント阻害剤(ICI)と光線力学的療...</td>\n",
" <td>食道がん、胃がん</td>\n",
" <td>一次治療として免疫チェックポイント阻害剤（ICI）を含む標準治療を予定される進行・再発食道が...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>The patient with unresectable or recurrent eso...</td>\n",
" <td>Has been diagnosed with HER2-positive gastric ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>Esophageal cancer, Gastric cancer</td>\n",
" <td>Cohort A: Nivolumab(240mg, every 2 weeks or 36...</td>\n",
" <td>[食道がん, 胃がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>610</th>\n",
" <td>jRCT2061220087</td>\n",
" <td>NCT05629585</td>\n",
" <td>NaN</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
" <td>乳癌</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房および／または腋窩リンパ節に浸潤性残存病変を有するI～II...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Participant must be >= 18 years at the time of...</td>\n",
" <td>Stage IV (metastatic) TNBC.\\r\\nHistory of prio...</td>\n",
" <td>18age old over</td>\n",
" <td>130age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>693</th>\n",
" <td>jRCT2031220276</td>\n",
" <td>NCT05307705</td>\n",
" <td>NaN</td>\n",
" <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
" <td>乳がん</td>\n",
" <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Have advanced breast cancer or another solid ...</td>\n",
" <td>-Medical Conditions\\r\\n -Colorectal cancer\\r\\n...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: LOXO-783\\r\\n Oral\\r\\n Other Name: LY384...</td>\n",
" <td>[乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>708</th>\n",
" <td>jRCT2031220203</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>初回腫瘍減量手術肉眼的完全切除後の進行卵巣癌を対象にパクリタキセル、カルボプラチン投与後のニ...</td>\n",
" <td>卵巣がん</td>\n",
" <td>診断時にステージIIIA/B/Cの高悪性度上皮性卵巣癌で、PDS後に残存病変を認めない患者を...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Female patient >= 18 years of age.\\r\\n2. Si...</td>\n",
" <td>1. Patient with clear cell adenocarcinoma or c...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will be included after surgery and wi...</td>\n",
" <td>[卵巣がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>753</th>\n",
" <td>jRCT2031220034</td>\n",
" <td>NCT04862663</td>\n",
" <td>NaN</td>\n",
" <td>局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を...</td>\n",
" <td>局所進行（切除不能）又は転移性乳癌</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Key inclusion criteria for both phases:\\n\\r\\n1...</td>\n",
" <td>Key exclusion criteria for both phases:\\r\\n1. ...</td>\n",
" <td>18age old over</td>\n",
" <td>99age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Capivasertib: PO BD 4 days on /3 days off per ...</td>\n",
" <td>[局所進行（切除不能）, 転移性乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>802</th>\n",
" <td>jRCT2031210585</td>\n",
" <td>NCT05123482</td>\n",
" <td>NaN</td>\n",
" <td>進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...</td>\n",
" <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
" <td>進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Age18 years or more\\n\\r\\n- Relapsed/metastat...</td>\n",
" <td>- Treatment with any of the following:\\n\\r\\n1....</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Sub-study1\\r\\nAZD8205 Monotherapy\\r\\nAZD8205 i...</td>\n",
" <td>[乳癌, 胆道癌, 卵巣癌, 子宮内膜癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>865</th>\n",
" <td>jRCT2052210099</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
" <td>乳がん</td>\n",
" <td>本治験の目的は，乳がん又はその疑いのある者，並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>単盲検</td>\n",
" <td>...</td>\n",
" <td>screening</td>\n",
" <td>Breast cancer (including suspected) \\r\\n(1) On...</td>\n",
" <td>(1) There is trauma with bleeding on the breas...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>The test using IGS-0001 will be performed twic...</td>\n",
" <td>[乳がん]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>20 rows × 39 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"12 jRCT2041240130 NaN NaN \n",
"59 jRCT2031240404 NaN NaN \n",
"201 jRCT2052240059 NaN NaN \n",
"234 jRCT2031240065 NaN NaN \n",
"257 jRCT2033240023 NaN NaN \n",
"271 jRCT2031230750 NCT06188559 NaN \n",
"279 jRCT2031230723 NCT06112379 NaN \n",
"311 jRCT2061230102 NCT06103864 NaN \n",
"396 jRCT2061230074 NCT05952557 NaN \n",
"467 jRCT2031230249 NCT05753501 NaN \n",
"509 jRCT2031230109 NCT05514054 NaN \n",
"514 jRCT2031230090 NaN NaN \n",
"515 jRCT2031230096 NCT05774951 NaN \n",
"582 jRCT2051220176 NaN NaN \n",
"610 jRCT2061220087 NCT05629585 NaN \n",
"693 jRCT2031220276 NCT05307705 NaN \n",
"708 jRCT2031220203 NaN NaN \n",
"753 jRCT2031220034 NCT04862663 NaN \n",
"802 jRCT2031210585 NCT05123482 NaN \n",
"865 jRCT2052210099 NaN NaN \n",
"\n",
" Title \\\n",
"12 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... \n",
"59 転移性HR+/HER2-乳がん及びその他の進行性固形がん患者を対象にCDK4阻害剤BGB-4... \n",
"201 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... \n",
"234 DNAミスマッチ修復機構欠損を有する進行性・転移性子宮体がん患者を対象に、一次治療として化学... \n",
"257 免疫チェックポイント阻害剤に対してacquired resistanceとなったがん患者を対... \n",
"271 治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，... \n",
"279 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... \n",
"311 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... \n",
"396 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... \n",
"467 [M23-647]B細胞性悪性腫瘍患者を対象としたBTK 分解誘導化合物ABBV-101 の... \n",
"509 EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... \n",
"514 MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ... \n",
"515 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... \n",
"582 切除不能進行再発食道がん及び胃がんに対する免疫チェックポイント阻害剤(ICI)と光線力学的療... \n",
"610 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... \n",
"693 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... \n",
"708 初回腫瘍減量手術肉眼的完全切除後の進行卵巣癌を対象にパクリタキセル、カルボプラチン投与後のニ... \n",
"753 局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を... \n",
"802 進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... \n",
"865 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... \n",
"\n",
" Target \\\n",
"12 肺がん \n",
"59 ・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳... \n",
"201 乳がん \n",
"234 子宮体がん \n",
"257 肺がん、食道がん、胃癌等の固形がん \n",
"271 HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 \n",
"279 乳癌 \n",
"311 乳癌 \n",
"396 乳がん、早期乳がん \n",
"467 血液がん \n",
"509 乳癌 \n",
"514 再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん \n",
"515 乳がん、早期乳がん \n",
"582 食道がん、胃がん \n",
"610 乳癌 \n",
"693 乳がん \n",
"708 卵巣がん \n",
"753 局所進行（切除不能）又は転移性乳癌 \n",
"802 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n",
"865 乳がん \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n",
"12 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... 2 NaN \n",
"59 サイクリン依存性キナーゼ 4 (CDK4) 阻害剤である BGB-43395 が、ホルモン受... 1 NaN \n",
"201 HSD17B4高メチル化（HSD17B4 hypermethylation：HH）を有するH... 2 NaN \n",
"234 dMMR/MSI-Hを有する再発又は進行子宮体癌患者を対象にdostarlimabの有効性及... 3 NaN \n",
"257 免疫チェックポイント阻害剤に対してacquired resistanceとなったがん患者（非... 1-2 NaN \n",
"271 治療 2 NaN \n",
"279 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... 3 NaN \n",
"311 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN \n",
"396 Treatment 3 NaN \n",
"467 ・ABBV-101 の安全性を明らかにし，忍容性を確認する\\r\\n・ABBV-101 の経口... 1 NaN \n",
"509 早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 3 NaN \n",
"514 再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する... 1 NaN \n",
"515 Treatment 3 NaN \n",
"582 一次治療として免疫チェックポイント阻害剤（ICI）を含む標準治療を予定される進行・再発食道が... 2 NaN \n",
"610 術前薬物療法後の外科的切除時に乳房および／または腋窩リンパ節に浸潤性残存病変を有するI～II... 3 NaN \n",
"693 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN \n",
"708 診断時にステージIIIA/B/Cの高悪性度上皮性卵巣癌で、PDS後に残存病変を認めない患者を... 2 NaN \n",
"753 Treatment 3 NaN \n",
"802 進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 1-2 NaN \n",
"865 本治験の目的は，乳がん又はその疑いのある者，並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN \n",
"\n",
" 無作為化 盲検化 ... purpose \\\n",
"12 無作為化比較 非盲検 ... treatment purpose \n",
"59 非無作為化比較 非盲検 ... treatment purpose \n",
"201 単一群 非盲検 ... diagnostic purpose \n",
"234 無作為化比較 非盲検 ... treatment purpose \n",
"257 単一群 非盲検 ... treatment purpose \n",
"271 無作為化比較 非盲検 ... treatment purpose \n",
"279 無作為化比較 非盲検 ... treatment purpose \n",
"311 無作為化比較 非盲検 ... treatment purpose \n",
"396 無作為化比較 非盲検 ... treatment purpose \n",
"467 単一群 非盲検 ... treatment purpose \n",
"509 無作為化比較 非盲検 ... treatment purpose \n",
"514 単一群 非盲検 ... treatment purpose \n",
"515 無作為化比較 非盲検 ... treatment purpose \n",
"582 単一群 非盲検 ... treatment purpose \n",
"610 無作為化比較 非盲検 ... treatment purpose \n",
"693 単一群 非盲検 ... treatment purpose \n",
"708 無作為化比較 非盲検 ... treatment purpose \n",
"753 無作為化比較 二重盲検 ... treatment purpose \n",
"802 単一群 非盲検 ... treatment purpose \n",
"865 単一群 単盲検 ... screening \n",
"\n",
" Inclusion Criteria \\\n",
"12 (1) Patients scheduled to undergo anatomical l... \n",
"59 -Phase 1a (Dose Escalation) and 1b (Dose Expan... \n",
"201 1. Histologically confirmed invasive breast ca... \n",
"234 1. Female patient is at least 18 years of age,... \n",
"257 1. Japanese patients aged 20 years or older at... \n",
"271 (1) Male or female, aged >=18 years at the tim... \n",
"279 1. Participant must be >= 18 years at the time... \n",
"311 Histologically or cytologically documented loc... \n",
"396 - Women and Men; 18 years or more at the time ... \n",
"467 -For Dose Escalation (Part 1) only: Participan... \n",
"509 -Have a diagnosis of ER+, HER2- early-stage, r... \n",
"514 Dose Escalation and Dose Expansion Cohorts\\r\\n... \n",
"515 - Women and Men, greater than or equal to 18 y... \n",
"582 The patient with unresectable or recurrent eso... \n",
"610 Participant must be >= 18 years at the time of... \n",
"693 -Have advanced breast cancer or another solid ... \n",
"708 1. Female patient >= 18 years of age.\\r\\n2. Si... \n",
"753 Key inclusion criteria for both phases:\\n\\r\\n1... \n",
"802 - Age18 years or more\\n\\r\\n- Relapsed/metastat... \n",
"865 Breast cancer (including suspected) \\r\\n(1) On... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"12 (1) Patients with a history of allergy to the ... 18age old over \n",
"59 -Prior therapy selectively targeting CDK4 (pri... 18age old over \n",
"201 1. History of other malignancy within the last... 20age old over \n",
"234 1. Patient has received neoadjuvant/adjuvant s... 18age old over \n",
"257 1. Patients with a history of severe drug hype... 20age old over \n",
"271 (1) Presence of brain or subdural metastases, ... 18age old over \n",
"279 1. As judged by the investigator, any evidence... 18age old over \n",
"311 As judged by investigator, severe or uncontrol... 18age old over \n",
"396 - Inoperable locally advanced or metastatic br... 18age old over \n",
"467 -Previously treated with a Bruton's tyrosine k... 18age old over \n",
"509 -Have any evidence of metastatic disease (incl... 18age old over \n",
"514 Dose Escalation and Expansion Cohorts\\r\\n1.\\tW... 18age old over \n",
"515 - Inoperable locally advanced or metastatic br... 18age old over \n",
"582 Has been diagnosed with HER2-positive gastric ... 18age old over \n",
"610 Stage IV (metastatic) TNBC.\\r\\nHistory of prio... 18age old over \n",
"693 -Medical Conditions\\r\\n -Colorectal cancer\\r\\n... 18age old over \n",
"708 1. Patient with clear cell adenocarcinoma or c... 18age old over \n",
"753 Key exclusion criteria for both phases:\\r\\n1. ... 18age old over \n",
"802 - Treatment with any of the following:\\n\\r\\n1.... 18age old over \n",
"865 (1) There is trauma with bleeding on the breas... 20age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria \\\n",
"12 No limit Both NaN \n",
"59 No limit Both NaN \n",
"201 No limit Female NaN \n",
"234 No limit Female NaN \n",
"257 No limit Both NaN \n",
"271 No limit Both NaN \n",
"279 No limit Both NaN \n",
"311 No limit Both NaN \n",
"396 No limit NaN NaN \n",
"467 No limit Both NaN \n",
"509 No limit Both NaN \n",
"514 No limit Female NaN \n",
"515 No limit Both NaN \n",
"582 No limit Both NaN \n",
"610 130age old under Both NaN \n",
"693 No limit Both NaN \n",
"708 No limit Female NaN \n",
"753 99age old under Both NaN \n",
"802 No limit Both NaN \n",
"865 No limit Female NaN \n",
"\n",
" Keyword \\\n",
"12 NaN \n",
"59 NaN \n",
"201 NaN \n",
"234 NaN \n",
"257 NaN \n",
"271 NaN \n",
"279 NaN \n",
"311 NaN \n",
"396 NaN \n",
"467 NaN \n",
"509 NaN \n",
"514 NaN \n",
"515 NaN \n",
"582 Esophageal cancer, Gastric cancer \n",
"610 NaN \n",
"693 NaN \n",
"708 NaN \n",
"753 NaN \n",
"802 NaN \n",
"865 NaN \n",
"\n",
" Intervention(s) \\\n",
"12 Treatment group\\r\\nAdminister GRA 1mg intraven... \n",
"59 -Drug: BGB-43395\\r\\nPlanned doses administered... \n",
"201 Omitting breast surgery after preoperative che... \n",
"234 Patients will be randomized 1:1 to receive eit... \n",
"257 Intramuscular injection of the investigational... \n",
"271 Generic Name:NA\\r\\nStudy Treatment in dose opt... \n",
"279 - Experimental arm: Dato-DXd plus durvalumab n... \n",
"311 Arm 1: Dato-DXd + durvalumab\\r\\nArm 2: Investi... \n",
"396 arm A: continue with SoC ET as directed by inv... \n",
"467 Drug: ABBV-101\\r\\nOral: Tablet \n",
"509 -Drug: Imlunestrant\\r\\n Administered orally.\\... \n",
"514 This is a Phase I dose escalation/expansion mu... \n",
"515 arm A: continue with SoC ET as directed by inv... \n",
"582 Cohort A: Nivolumab(240mg, every 2 weeks or 36... \n",
"610 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n",
"693 -Drug: LOXO-783\\r\\n Oral\\r\\n Other Name: LY384... \n",
"708 Patients will be included after surgery and wi... \n",
"753 Capivasertib: PO BD 4 days on /3 days off per ... \n",
"802 Sub-study1\\r\\nAZD8205 Monotherapy\\r\\nAZD8205 i... \n",
"865 The test using IGS-0001 will be performed twic... \n",
"\n",
" TargetWord \n",
"12 [肺がん] \n",
"59 [進行性固形腫瘍, 進行性乳がん, 転移性乳がん, ホルモン受容体陽性乳がん, ホルモン受容... \n",
"201 [乳がん] \n",
"234 [子宮体がん] \n",
"257 [肺がん, 食道がん, 胃癌等の固形がん] \n",
"271 [HER2 陽性, HER2 低発現の切除不能, 転移性乳癌] \n",
"279 [乳癌] \n",
"311 [乳癌] \n",
"396 [乳がん, 早期乳がん] \n",
"467 [血液がん] \n",
"509 [乳癌] \n",
"514 [再発, 難治性の局所進行性, 転移性乳がん, トリプルネガティブ乳がん] \n",
"515 [乳がん, 早期乳がん] \n",
"582 [食道がん, 胃がん] \n",
"610 [乳癌] \n",
"693 [乳がん] \n",
"708 [卵巣がん] \n",
"753 [局所進行（切除不能）, 転移性乳癌] \n",
"802 [乳癌, 胆道癌, 卵巣癌, 子宮内膜癌] \n",
"865 [乳がん] \n",
"\n",
"[20 rows x 39 columns]"
]
},
"execution_count": 68,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"# ターゲットリスト全体を処理\n",
"matched_indices = []\n",
"target_vecs_list = []\n",
"cosine_scores_list = []\n",
"for idx, target_words in enumerate(basedf['TargetWord']):\n",
" # ターゲット内の各単語をベクトル化\n",
" target_vecs = encode_text(target_words)\n",
" # コサイン類似度を計算\n",
" cosine_scores = torch.nn.functional.cosine_similarity(query_vec, target_vecs)\n",
" target_vecs_list.append(target_vecs)\n",
" cosine_scores_list.append(cosine_scores)\n",
" # 閾値を超えるか確認\n",
" if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n",
" matched_indices.append(idx)\n",
"\n",
"# 抽出\n",
"matched_df = basedf.iloc[matched_indices]\n",
"matched_df"
]
},
{
"cell_type": "code",
"execution_count": 69,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"[tensor([0.8485]),\n",
" tensor([0.8322, 0.8710]),\n",
" tensor([0.8630]),\n",
" tensor([0.8748, 0.8663]),\n",
" tensor([0.9373]),\n",
" tensor([0.8615, 0.8576]),\n",
" tensor([0.8443]),\n",
" tensor([0.8511]),\n",
" tensor([0.8320, 0.8452]),\n",
" tensor([0.8485]),\n",
" tensor([0.8681]),\n",
" tensor([0.8585]),\n",
" tensor([0.8489]),\n",
" tensor([0.8535]),\n",
" tensor([0.9058]),\n",
" tensor([0.8473, 0.9020]),\n",
" tensor([0.8587]),\n",
" tensor([0.8621]),\n",
" tensor([0.8526]),\n",
" tensor([0.8363]),\n",
" tensor([0.8573]),\n",
" tensor([0.7646, 0.7990]),\n",
" tensor([0.9068, 0.8733, 0.8775]),\n",
" tensor([0.8584]),\n",
" tensor([0.8584]),\n",
" tensor([0.8624]),\n",
" tensor([0.8456]),\n",
" tensor([0.8959]),\n",
" tensor([0.8844]),\n",
" tensor([0.8842, 0.9356, 0.9305, 0.9065, 0.8970]),\n",
" tensor([0.8691, 0.8630, 0.8718]),\n",
" tensor([0.8758]),\n",
" tensor([0.8630]),\n",
" tensor([0.8611]),\n",
" tensor([0.8630]),\n",
" tensor([0.8963]),\n",
" tensor([0.8601]),\n",
" tensor([0.8040, 0.8439]),\n",
" tensor([0.8789, 0.8568]),\n",
" tensor([0.8110, 0.8643, 0.8400, 0.9012]),\n",
" tensor([0.8604]),\n",
" tensor([0.8752, 0.8826, 0.8916, 0.8565]),\n",
" tensor([0.9091, 0.8941, 0.8630]),\n",
" tensor([0.8391, 0.8505]),\n",
" tensor([0.8625]),\n",
" tensor([0.8507]),\n",
" tensor([0.8583, 0.8685]),\n",
" tensor([0.8758]),\n",
" tensor([0.8597]),\n",
" tensor([0.8707]),\n",
" tensor([0.8908]),\n",
" tensor([0.8480]),\n",
" tensor([0.8567]),\n",
" tensor([0.8752, 0.8763, 0.8826]),\n",
" tensor([0.8630]),\n",
" tensor([0.8497]),\n",
" tensor([0.8395, 0.8532, 0.7941, 0.8583]),\n",
" tensor([0.8630]),\n",
" tensor([0.8254, 0.8873]),\n",
" tensor([0.8758]),\n",
" tensor([0.8806]),\n",
" tensor([0.8152, 0.8277, 0.8346, 0.8746]),\n",
" tensor([0.8478]),\n",
" tensor([0.8758]),\n",
" tensor([0.8781]),\n",
" tensor([0.8615]),\n",
" tensor([0.8446, 0.8641]),\n",
" tensor([0.8733]),\n",
" tensor([0.8507]),\n",
" tensor([0.8584]),\n",
" tensor([0.8630]),\n",
" tensor([0.8545]),\n",
" tensor([0.8819]),\n",
" tensor([0.8969, 0.8613, 0.8482, 0.8693, 0.8598]),\n",
" tensor([0.8688]),\n",
" tensor([0.8625]),\n",
" tensor([0.8455, 0.8619]),\n",
" tensor([0.8788]),\n",
" tensor([0.8540]),\n",
" tensor([0.8625]),\n",
" tensor([0.8630]),\n",
" tensor([0.8664]),\n",
" tensor([0.8630]),\n",
" tensor([0.8459, 0.8211, 0.8484]),\n",
" tensor([0.8508, 0.8430, 0.8313, 0.8702]),\n",
" tensor([0.8469]),\n",
" tensor([0.9016]),\n",
" tensor([0.8630]),\n",
" tensor([0.8379]),\n",
" tensor([0.8558, 0.8561, 0.8513]),\n",
" tensor([0.8582, 0.8528]),\n",
" tensor([0.8582]),\n",
" tensor([0.8536]),\n",
" tensor([0.8804, 0.8691, 0.8711]),\n",
" tensor([0.8377, 0.8560, 0.8276]),\n",
" tensor([0.8604]),\n",
" tensor([0.8301, 0.8577]),\n",
" tensor([0.8410]),\n",
" tensor([0.8664]),\n",
" tensor([0.8473, 0.8524, 0.8974]),\n",
" tensor([0.8473, 0.8524, 0.8974]),\n",
" tensor([1.]),\n",
" tensor([0.8547]),\n",
" tensor([0.8540]),\n",
" tensor([0.8630]),\n",
" tensor([0.8615, 0.8576, 0.8696]),\n",
" tensor([0.9083, 0.8155, 0.8555, 0.8375, 0.8585]),\n",
" tensor([0.8624, 0.8528]),\n",
" tensor([0.8630]),\n",
" tensor([0.8584]),\n",
" tensor([0.8347]),\n",
" tensor([0.8630]),\n",
" tensor([0.8526]),\n",
" tensor([0.9058]),\n",
" tensor([0.8624]),\n",
" tensor([0.8597]),\n",
" tensor([0.8752, 0.8763, 0.8826]),\n",
" tensor([0.8305, 0.8894]),\n",
" tensor([0.9246]),\n",
" tensor([0.8630]),\n",
" tensor([0.8611]),\n",
" tensor([0.9068, 0.8908]),\n",
" tensor([0.8708]),\n",
" tensor([0.8587]),\n",
" tensor([0.8347]),\n",
" tensor([0.8959]),\n",
" tensor([0.8711]),\n",
" tensor([0.8711]),\n",
" tensor([0.8388, 0.8499]),\n",
" tensor([0.9373, 0.9130, 0.8716]),\n",
" tensor([0.8913, 0.8613, 0.8677, 0.8699, 0.8787, 0.8538, 0.8325]),\n",
" tensor([0.8540]),\n",
" tensor([0.8514]),\n",
" tensor([0.8388, 0.8499]),\n",
" tensor([0.8457, 0.8334, 0.9242]),\n",
" tensor([0.8758]),\n",
" tensor([0.8959]),\n",
" tensor([0.8841]),\n",
" tensor([0.9522]),\n",
" tensor([0.8630]),\n",
" tensor([0.8584]),\n",
" tensor([0.8604]),\n",
" tensor([0.8525]),\n",
" tensor([0.8535]),\n",
" tensor([0.8662]),\n",
" tensor([0.8639]),\n",
" tensor([0.8466, 0.8730]),\n",
" tensor([0.8337, 0.9098]),\n",
" tensor([0.8670]),\n",
" tensor([0.8577]),\n",
" tensor([0.8863, 0.8752]),\n",
" tensor([0.8630]),\n",
" tensor([0.8315, 0.8696]),\n",
" tensor([0.8362, 0.9098]),\n",
" tensor([0.8380]),\n",
" tensor([0.8540]),\n",
" tensor([0.9522]),\n",
" tensor([0.8908]),\n",
" tensor([0.8305, 0.8000, 0.8520]),\n",
" tensor([0.8540]),\n",
" tensor([0.8673]),\n",
" tensor([0.8593]),\n",
" tensor([0.8604]),\n",
" tensor([0.8203, 0.8343, 0.7933]),\n",
" tensor([0.8391, 0.8621]),\n",
" tensor([0.8368, 0.8635]),\n",
" tensor([0.8365, 0.8518, 0.8365, 0.8411]),\n",
" tensor([0.8391, 0.8505]),\n",
" tensor([0.8540]),\n",
" tensor([0.8536, 0.8536]),\n",
" tensor([0.8248, 0.7948, 0.8418, 0.8342, 0.8219]),\n",
" tensor([0.8521]),\n",
" tensor([0.8106, 0.8684]),\n",
" tensor([0.8510]),\n",
" tensor([0.8446]),\n",
" tensor([0.8541, 0.8603]),\n",
" tensor([0.8789, 0.8576, 0.8710]),\n",
" tensor([0.8631]),\n",
" tensor([0.8510]),\n",
" tensor([0.8523]),\n",
" tensor([0.8423]),\n",
" tensor([0.8908]),\n",
" tensor([0.8540]),\n",
" tensor([0.8376, 0.8768]),\n",
" tensor([0.8051, 0.8686]),\n",
" tensor([0.8630]),\n",
" tensor([0.8630, 0.8839]),\n",
" tensor([0.8604]),\n",
" tensor([0.8051]),\n",
" tensor([0.8688]),\n",
" tensor([0.8562]),\n",
" tensor([0.8562, 0.8553, 0.8430, 0.8563]),\n",
" tensor([0.8586]),\n",
" tensor([0.8458, 0.8616]),\n",
" tensor([0.8375, 0.8453]),\n",
" tensor([0.8540]),\n",
" tensor([0.8603, 0.8568, 0.8696]),\n",
" tensor([0.8450]),\n",
" tensor([0.8371, 0.8642, 0.8535]),\n",
" tensor([0.8417, 0.8689]),\n",
" tensor([0.9093]),\n",
" tensor([0.8728]),\n",
" tensor([0.9990, 0.9460]),\n",
" tensor([0.8443, 0.8873]),\n",
" tensor([0.8759]),\n",
" tensor([0.8752]),\n",
" tensor([0.8440]),\n",
" tensor([0.7623, 0.8737, 0.8236, 0.8576, 0.8696, 0.8687]),\n",
" tensor([0.8630]),\n",
" tensor([0.8314, 0.8953]),\n",
" tensor([0.8388, 0.8499]),\n",
" tensor([0.8360, 0.8724]),\n",
" tensor([0.8303, 0.8760, 0.8303, 0.8781, 0.8303, 0.8612]),\n",
" tensor([0.8384, 0.8511]),\n",
" tensor([0.8391, 0.8590]),\n",
" tensor([0.8247, 0.8847, 0.8139, 0.8356]),\n",
" tensor([0.8628]),\n",
" tensor([0.8732, 0.8518, 0.7789]),\n",
" tensor([0.8204, 0.8629]),\n",
" tensor([0.8384, 0.7728, 0.8089, 0.8722]),\n",
" tensor([0.8061, 0.8273]),\n",
" tensor([0.8435]),\n",
" tensor([0.8344, 0.8426, 0.8477]),\n",
" tensor([0.8838, 0.8694]),\n",
" tensor([0.8535]),\n",
" tensor([0.8411]),\n",
" tensor([0.8804]),\n",
" tensor([0.8485]),\n",
" tensor([0.8155, 0.8625]),\n",
" tensor([0.8511, 0.8162, 0.8280, 0.8599, 0.8879]),\n",
" tensor([0.8422, 0.7904, 0.8108, 0.8225]),\n",
" tensor([0.8901]),\n",
" tensor([0.8508]),\n",
" tensor([0.8806, 0.8688]),\n",
" tensor([0.8786]),\n",
" tensor([0.9182]),\n",
" tensor([0.8405]),\n",
" tensor([0.8563]),\n",
" tensor([0.8630]),\n",
" tensor([0.8495]),\n",
" tensor([0.8110, 0.8427, 0.8705]),\n",
" tensor([0.8525]),\n",
" tensor([0.8106, 0.8752]),\n",
" tensor([0.8688]),\n",
" tensor([0.8604]),\n",
" tensor([0.8540]),\n",
" tensor([0.8540]),\n",
" tensor([0.8809]),\n",
" tensor([0.8789, 0.8576, 0.8790, 0.8781]),\n",
" tensor([0.8525]),\n",
" tensor([0.8846]),\n",
" tensor([0.9068]),\n",
" tensor([0.8602, 0.8571, 0.8578, 0.8484]),\n",
" tensor([0.8347]),\n",
" tensor([0.8501, 0.9079]),\n",
" tensor([0.9522]),\n",
" tensor([0.8107, 0.8577]),\n",
" tensor([0.8938, 0.8839, 0.8568]),\n",
" tensor([0.8391, 0.8348, 0.9305, 0.9071]),\n",
" tensor([0.9990, 0.9460]),\n",
" tensor([0.8587, 0.8379, 0.8649]),\n",
" tensor([0.8540]),\n",
" tensor([0.8604]),\n",
" tensor([0.8264, 0.8635, 0.8576]),\n",
" tensor([0.8264]),\n",
" tensor([0.9071]),\n",
" tensor([0.8395]),\n",
" tensor([0.8179, 0.8403]),\n",
" tensor([0.8630]),\n",
" tensor([0.8540]),\n",
" tensor([0.8409, 0.8956]),\n",
" tensor([0.8602, 0.8630, 0.8836]),\n",
" tensor([0.8908]),\n",
" tensor([0.9068]),\n",
" tensor([0.8309, 0.8598]),\n",
" tensor([0.8576, 0.8500]),\n",
" tensor([0.8625]),\n",
" tensor([0.8804]),\n",
" tensor([0.8359, 0.8612, 0.8127]),\n",
" tensor([0.8163, 0.8752]),\n",
" tensor([0.8806]),\n",
" tensor([0.9118, 0.9205]),\n",
" tensor([0.8786]),\n",
" tensor([0.8577]),\n",
" tensor([0.8506]),\n",
" tensor([0.8201, 0.8684]),\n",
" tensor([0.8499]),\n",
" tensor([0.8391, 0.8505]),\n",
" tensor([0.8604]),\n",
" tensor([0.8535]),\n",
" tensor([0.9522]),\n",
" tensor([0.8773]),\n",
" tensor([0.8280]),\n",
" tensor([0.8488]),\n",
" tensor([0.8540]),\n",
" tensor([0.8459]),\n",
" tensor([0.8514, 0.8533]),\n",
" tensor([0.8249, 0.8579]),\n",
" tensor([0.8510]),\n",
" tensor([0.8597, 0.8345, 0.9077, 0.8147, 0.8507]),\n",
" tensor([0.8188, 0.8284]),\n",
" tensor([0.8393]),\n",
" tensor([0.8322, 0.8710]),\n",
" tensor([0.8630]),\n",
" tensor([0.8823]),\n",
" tensor([0.8659]),\n",
" tensor([0.8630]),\n",
" tensor([0.8630]),\n",
" tensor([0.8907, 0.8770, 0.8625, 0.9053, 0.8711, 0.8543, 0.8684]),\n",
" tensor([0.8658]),\n",
" tensor([0.8503, 0.8373]),\n",
" tensor([0.8517]),\n",
" tensor([0.8630]),\n",
" tensor([0.8540]),\n",
" tensor([0.8365, 0.7996, 0.8437, 0.8365, 0.7996, 0.8523]),\n",
" tensor([0.8804]),\n",
" tensor([0.8908]),\n",
" tensor([0.8604]),\n",
" tensor([0.8649, 0.8198, 0.8309]),\n",
" tensor([0.8733]),\n",
" tensor([1.]),\n",
" tensor([0.8749]),\n",
" tensor([0.8733, 0.8395, 0.8583]),\n",
" tensor([0.8806]),\n",
" tensor([0.9128]),\n",
" tensor([0.8630]),\n",
" tensor([0.8540]),\n",
" tensor([0.8552]),\n",
" tensor([0.8908]),\n",
" tensor([0.8577]),\n",
" tensor([0.8604]),\n",
" tensor([0.8463, 0.8154, 0.8398, 0.8542, 0.8673, 0.8961]),\n",
" tensor([0.8551, 0.9088]),\n",
" tensor([0.8841]),\n",
" tensor([0.8358]),\n",
" tensor([0.8806]),\n",
" tensor([0.8789, 0.8576]),\n",
" tensor([0.8630]),\n",
" tensor([0.8232, 0.9240]),\n",
" tensor([0.8584]),\n",
" tensor([0.8242]),\n",
" tensor([0.8471]),\n",
" tensor([0.8499]),\n",
" tensor([0.8526]),\n",
" tensor([0.8513, 0.8181, 0.8358, 0.8695]),\n",
" tensor([0.8433]),\n",
" tensor([0.8630]),\n",
" tensor([0.8789, 0.8576]),\n",
" tensor([0.8405]),\n",
" tensor([0.8584]),\n",
" tensor([0.8580]),\n",
" tensor([0.8496]),\n",
" tensor([0.8540]),\n",
" tensor([0.8434, 0.8146, 0.8664]),\n",
" tensor([0.8375, 0.8562]),\n",
" tensor([0.8319, 0.8758]),\n",
" tensor([0.8725, 0.8489, 0.8651]),\n",
" tensor([0.9505, 0.8707, 0.9088, 0.8914]),\n",
" tensor([0.8604]),\n",
" tensor([0.8315, 0.8696]),\n",
" tensor([0.8535]),\n",
" tensor([0.8290, 0.8370]),\n",
" tensor([0.8908]),\n",
" tensor([0.8182, 0.8864, 0.8526]),\n",
" tensor([0.8841]),\n",
" tensor([0.8685]),\n",
" tensor([0.8106, 0.8752]),\n",
" tensor([0.8770]),\n",
" tensor([0.8430, 0.8630, 0.8430, 0.8706, 0.8430, 0.8658]),\n",
" tensor([0.8265]),\n",
" tensor([0.8526]),\n",
" tensor([0.8559]),\n",
" tensor([0.8161, 0.8664]),\n",
" tensor([0.8586]),\n",
" tensor([1.]),\n",
" tensor([0.8256, 0.8344]),\n",
" tensor([0.8712, 0.8568]),\n",
" tensor([0.8467]),\n",
" tensor([0.8604]),\n",
" tensor([0.8669, 0.8661]),\n",
" tensor([0.8630, 0.8427, 0.8530, 0.8497, 0.8509, 0.8302]),\n",
" tensor([0.8336, 0.8468, 0.8465]),\n",
" tensor([0.8380, 0.8434, 0.8507]),\n",
" tensor([0.8220, 0.8638]),\n",
" tensor([0.8623]),\n",
" tensor([0.8540]),\n",
" tensor([0.8758]),\n",
" tensor([0.8375, 0.8453]),\n",
" tensor([0.8776]),\n",
" tensor([0.8584]),\n",
" tensor([0.8583, 0.8142]),\n",
" tensor([0.7930, 0.7781, 0.8385]),\n",
" tensor([0.8479]),\n",
" tensor([0.8923, 0.8914, 0.7692, 0.8157]),\n",
" tensor([0.8373, 0.8890]),\n",
" tensor([0.8785]),\n",
" tensor([0.8584]),\n",
" tensor([0.8405]),\n",
" tensor([0.8159, 0.8669]),\n",
" tensor([0.8381, 0.8489]),\n",
" tensor([0.8450]),\n",
" tensor([0.8347]),\n",
" tensor([0.8554]),\n",
" tensor([0.8535, 0.8582]),\n",
" tensor([0.8536]),\n",
" tensor([0.8561]),\n",
" tensor([0.8540]),\n",
" tensor([0.8914]),\n",
" tensor([0.8101, 0.8767, 0.8590, 0.8398]),\n",
" tensor([0.8797]),\n",
" tensor([0.8584]),\n",
" tensor([0.8615, 0.8568, 0.8696]),\n",
" tensor([0.8419]),\n",
" tensor([0.8385]),\n",
" tensor([0.8662]),\n",
" tensor([0.8648])]"
]
},
"execution_count": 69,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"cosine_scores_list"
]
},
{
"cell_type": "code",
"execution_count": 70,
"metadata": {},
"outputs": [],
"source": [
"# 全データのターゲット列をベクトル化\n",
"target_list = basedf['Target'].tolist()\n",
"\n",
"target_vecs = encode_text(target_list)\n",
" # コサイン類似度を計算\n",
"cosine_scores = torch.nn.functional.cosine_similarity(query_vec, target_vecs)"
]
},
{
"cell_type": "code",
"execution_count": 71,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCT2041240130</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
" <td>肺がん</td>\n",
" <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
" <td>(1) Patients with a history of allergy to the ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Treatment group\\r\\nAdminister GRA 1mg intraven...</td>\n",
" <td>[肺がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>201</th>\n",
" <td>jRCT2052240059</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
" <td>乳がん</td>\n",
" <td>HSD17B4高メチル化（HSD17B4 hypermethylation：HH）を有するH...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Histologically confirmed invasive breast ca...</td>\n",
" <td>1. History of other malignancy within the last...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Omitting breast surgery after preoperative che...</td>\n",
" <td>[乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>279</th>\n",
" <td>jRCT2031230723</td>\n",
" <td>NCT06112379</td>\n",
" <td>NaN</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>乳癌</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Participant must be >= 18 years at the time...</td>\n",
" <td>1. As judged by the investigator, any evidence...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>311</th>\n",
" <td>jRCT2061230102</td>\n",
" <td>NCT06103864</td>\n",
" <td>NaN</td>\n",
" <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
" <td>乳癌</td>\n",
" <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Histologically or cytologically documented loc...</td>\n",
" <td>As judged by investigator, severe or uncontrol...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd + durvalumab\\r\\nArm 2: Investi...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>396</th>\n",
" <td>jRCT2061230074</td>\n",
" <td>NCT05952557</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men; 18 years or more at the time ...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[乳がん, 早期乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>509</th>\n",
" <td>jRCT2031230109</td>\n",
" <td>NCT05514054</td>\n",
" <td>NaN</td>\n",
" <td>EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...</td>\n",
" <td>乳癌</td>\n",
" <td>早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Have a diagnosis of ER+, HER2- early-stage, r...</td>\n",
" <td>-Have any evidence of metastatic disease (incl...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: Imlunestrant\\r\\n Administered orally.\\...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>515</th>\n",
" <td>jRCT2031230096</td>\n",
" <td>NCT05774951</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men, greater than or equal to 18 y...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[乳がん, 早期乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>610</th>\n",
" <td>jRCT2061220087</td>\n",
" <td>NCT05629585</td>\n",
" <td>NaN</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
" <td>乳癌</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房および／または腋窩リンパ節に浸潤性残存病変を有するI～II...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Participant must be >= 18 years at the time of...</td>\n",
" <td>Stage IV (metastatic) TNBC.\\r\\nHistory of prio...</td>\n",
" <td>18age old over</td>\n",
" <td>130age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
" <td>[乳癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>693</th>\n",
" <td>jRCT2031220276</td>\n",
" <td>NCT05307705</td>\n",
" <td>NaN</td>\n",
" <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
" <td>乳がん</td>\n",
" <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Have advanced breast cancer or another solid ...</td>\n",
" <td>-Medical Conditions\\r\\n -Colorectal cancer\\r\\n...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: LOXO-783\\r\\n Oral\\r\\n Other Name: LY384...</td>\n",
" <td>[乳がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>865</th>\n",
" <td>jRCT2052210099</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
" <td>乳がん</td>\n",
" <td>本治験の目的は，乳がん又はその疑いのある者，並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>単盲検</td>\n",
" <td>...</td>\n",
" <td>screening</td>\n",
" <td>Breast cancer (including suspected) \\r\\n(1) On...</td>\n",
" <td>(1) There is trauma with bleeding on the breas...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>The test using IGS-0001 will be performed twic...</td>\n",
" <td>[乳がん]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>10 rows × 39 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"12 jRCT2041240130 NaN NaN \n",
"201 jRCT2052240059 NaN NaN \n",
"279 jRCT2031230723 NCT06112379 NaN \n",
"311 jRCT2061230102 NCT06103864 NaN \n",
"396 jRCT2061230074 NCT05952557 NaN \n",
"509 jRCT2031230109 NCT05514054 NaN \n",
"515 jRCT2031230096 NCT05774951 NaN \n",
"610 jRCT2061220087 NCT05629585 NaN \n",
"693 jRCT2031220276 NCT05307705 NaN \n",
"865 jRCT2052210099 NaN NaN \n",
"\n",
" Title Target \\\n",
"12 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... 肺がん \n",
"201 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... 乳がん \n",
"279 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... 乳癌 \n",
"311 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... 乳癌 \n",
"396 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... 乳がん、早期乳がん \n",
"509 EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... 乳癌 \n",
"515 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... 乳がん、早期乳がん \n",
"610 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... 乳癌 \n",
"693 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... 乳がん \n",
"865 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... 乳がん \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 無作為化 \\\n",
"12 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... 2 NaN 無作為化比較 \n",
"201 HSD17B4高メチル化（HSD17B4 hypermethylation：HH）を有するH... 2 NaN 単一群 \n",
"279 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... 3 NaN 無作為化比較 \n",
"311 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN 無作為化比較 \n",
"396 Treatment 3 NaN 無作為化比較 \n",
"509 早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 3 NaN 無作為化比較 \n",
"515 Treatment 3 NaN 無作為化比較 \n",
"610 術前薬物療法後の外科的切除時に乳房および／または腋窩リンパ節に浸潤性残存病変を有するI～II... 3 NaN 無作為化比較 \n",
"693 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN 単一群 \n",
"865 本治験の目的は，乳がん又はその疑いのある者，並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN 単一群 \n",
"\n",
" 盲検化 ... purpose \\\n",
"12 非盲検 ... treatment purpose \n",
"201 非盲検 ... diagnostic purpose \n",
"279 非盲検 ... treatment purpose \n",
"311 非盲検 ... treatment purpose \n",
"396 非盲検 ... treatment purpose \n",
"509 非盲検 ... treatment purpose \n",
"515 非盲検 ... treatment purpose \n",
"610 非盲検 ... treatment purpose \n",
"693 非盲検 ... treatment purpose \n",
"865 単盲検 ... screening \n",
"\n",
" Inclusion Criteria \\\n",
"12 (1) Patients scheduled to undergo anatomical l... \n",
"201 1. Histologically confirmed invasive breast ca... \n",
"279 1. Participant must be >= 18 years at the time... \n",
"311 Histologically or cytologically documented loc... \n",
"396 - Women and Men; 18 years or more at the time ... \n",
"509 -Have a diagnosis of ER+, HER2- early-stage, r... \n",
"515 - Women and Men, greater than or equal to 18 y... \n",
"610 Participant must be >= 18 years at the time of... \n",
"693 -Have advanced breast cancer or another solid ... \n",
"865 Breast cancer (including suspected) \\r\\n(1) On... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"12 (1) Patients with a history of allergy to the ... 18age old over \n",
"201 1. History of other malignancy within the last... 20age old over \n",
"279 1. As judged by the investigator, any evidence... 18age old over \n",
"311 As judged by investigator, severe or uncontrol... 18age old over \n",
"396 - Inoperable locally advanced or metastatic br... 18age old over \n",
"509 -Have any evidence of metastatic disease (incl... 18age old over \n",
"515 - Inoperable locally advanced or metastatic br... 18age old over \n",
"610 Stage IV (metastatic) TNBC.\\r\\nHistory of prio... 18age old over \n",
"693 -Medical Conditions\\r\\n -Colorectal cancer\\r\\n... 18age old over \n",
"865 (1) There is trauma with bleeding on the breas... 20age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria Keyword \\\n",
"12 No limit Both NaN NaN \n",
"201 No limit Female NaN NaN \n",
"279 No limit Both NaN NaN \n",
"311 No limit Both NaN NaN \n",
"396 No limit NaN NaN NaN \n",
"509 No limit Both NaN NaN \n",
"515 No limit Both NaN NaN \n",
"610 130age old under Both NaN NaN \n",
"693 No limit Both NaN NaN \n",
"865 No limit Female NaN NaN \n",
"\n",
" Intervention(s) TargetWord \n",
"12 Treatment group\\r\\nAdminister GRA 1mg intraven... [肺がん] \n",
"201 Omitting breast surgery after preoperative che... [乳がん] \n",
"279 - Experimental arm: Dato-DXd plus durvalumab n... [乳癌] \n",
"311 Arm 1: Dato-DXd + durvalumab\\r\\nArm 2: Investi... [乳癌] \n",
"396 arm A: continue with SoC ET as directed by inv... [乳がん, 早期乳がん] \n",
"509 -Drug: Imlunestrant\\r\\n Administered orally.\\... [乳癌] \n",
"515 arm A: continue with SoC ET as directed by inv... [乳がん, 早期乳がん] \n",
"610 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... [乳癌] \n",
"693 -Drug: LOXO-783\\r\\n Oral\\r\\n Other Name: LY384... [乳がん] \n",
"865 The test using IGS-0001 will be performed twic... [乳がん] \n",
"\n",
"[10 rows x 39 columns]"
]
},
"execution_count": 71,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n",
"# 入れ子リストをフラットなリストに変換\n",
"flat_indices_d = [idx[0] for idx in matched_indices_d]\n",
"\n",
"# 抽出\n",
"matched_df_d = basedf.iloc[flat_indices_d]\n",
"matched_df_d\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"\n",
"\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"\n"
]
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|